Revumenib plus chemo for newly diagnosed AML with NPM1 mutation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, revumenib, combined with strong chemotherapy for people with a specific type of AML (NPM1 mutation). The goal is to see if adding revumenib helps treat the leukemia better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed AML that hasn't been treated yet.
- Your AML must have a change in the NPM1 gene (NPM1 mutation).
- You should be healthy enough for intensive chemotherapy, with good organ function.
- You must not be pregnant, and agree to use birth control if needed.
- You cannot have certain heart rhythm problems or take medicines that affect them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
This trial tests a new drug called revumenib combined with a strong chemotherapy regimen (7+3) and midostaurin for people with newly diagnosed AML that has specific gene mutations (FLT3 and NPM1). The goal is to see if this combination works better than standard treatments.
This trial tests adding a new targeted drug, revumenib, to two standard AML medicines (azacitidine and venetoclax) for adults with a specific gene change (NPM1 mutation or KMT2A rearrangement) who cannot receive strong chemotherapy. The goal is to see if the combination works better.
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
This trial tests a new targeted drug (revumenib) combined with standard chemotherapy (FLA) for children and young adults whose acute myeloid leukemia (AML) has a specific genetic change (NUP98 rearrangement) and has either not responded to initial treatment or returned after remission.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Hear when a new Acute Myeloid Leukemias trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.